Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neuMouse Model of Breast Cancer
- 1 August 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (15) , 7748-7757
- https://doi.org/10.1158/0008-5472.can-05-4469
Abstract
The HER-2/neu oncogene has >25 HLA epitopes, yet only one FVB/N mouse CD8+ T-cell epitope has been mapped to date. This epitope has been termed the immunodominant epitope for the FVB/N mouse, but we propose that the vaccination strategy determines the dominance of epitopes. Using a series of overlapping peptides, we have mapped another CD8+ T-cell epitope that emerges in the FVB/N mouse following vaccination with Listeria monocytogenes–based vaccines that express fragments of HER-2/neu. Following the identification of this novel H-2Kq-restricted epitope, we sought to compare the T-cell response to this epitope with the previously identified PDSLRDLSVF epitope. This newly identified epitope and the previously identified epitope lie within fragments contained in different vaccines, the PDSLRDLSVF epitope in Lm-LLO-EC2 and the newly identified PYNYLSTEV epitope in Lm-LLO-EC1; thus, it has been possible to compare the responses of these epitopes independent of any competing response between the epitopes. CTL analysis of individual peptide-pulsed target cells and intracellular cytokine stain for IFN-γ produced by splenocytes from Lm-LLO-EC1 compared with Lm-LLO-EC2 vaccinated FVB/N mice shows that there is no difference between the responses generated to either of these epitopes. We also show that the avidity of the CD8+ T cells for either of these epitopes is similar based on the concentration of peptide necessary to mediate similar levels of lysis of target cells. In addition, HER-2/neu DNA vaccination followed by CTL analysis further showed that both of these peptides can emerge as epitopes. (Cancer Res 2006; 66(15): 7748-57)Keywords
This publication has 51 references indexed in Scilit:
- Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune responseThe Journal of Experimental Medicine, 2005
- Peripheral Tolerance of CD8 T LymphocytesImmunity, 2005
- HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinationsGene Therapy, 2002
- Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.The Journal of Experimental Medicine, 1994
- Antigen Processing, Where Tumor-Specific T-Cell Responses BeginJournal of Immunotherapy, 1993
- The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure.The Journal of Experimental Medicine, 1991
- Molecular evidence that the H-2D and H-2L genes arose by duplication. Differences between the evolution of the class I genes in mice and humans.The Journal of Experimental Medicine, 1990
- The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumor-specific antigens.The Journal of Experimental Medicine, 1988
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- CELLULAR RESISTANCE TO INFECTIONThe Journal of Experimental Medicine, 1962